BCTXZ — BriaCell Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1610820 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Apr 2026 | 0 | — | -7,620,794 | -7,164,507 | 27,071,310 | 6,880,221 | 3,662,350 |
| Jan 2026 | 0 | — | -7,531,266 | -7,221,820 | 33,594,454 | 29,903,628 | 3,380,646 |
| Oct 2025 | 0 | — | -8,322,943 | -8,197,565 | 13,075,050 | 2,714,012 | 3,724,646 |
| Apr 2025 | 0 | — | -6,328,255 | -6,126,902 | 17,001,798 | 12,460,253 | 5,060,645 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,855,229
Investing CF
$-8,900,576
Financing CF
$42,588,817
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-09-13
Balance + Analyst (yfinance extras)
Retained Earnings
$-134,339,456
Inventory
—
Receivables
$2,588,749
ST Investments
$15,924,204
EBIT TTM
$-29,249,583
Pretax Income TTM
$-29,037,205
Interest Exp TTM
$66,610
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jul 2024 | 0 | -33,330,076 | -4,791,466 | 5,872,261 | 8,557,193 | -2,382,410 | -24,126,128 |
| Jul 2023 | 0 | -23,272,264 | -20,302,394 | 27,163,577 | 30,940,758 | -3,777,181 | -23,744,860 |
| Jul 2022 | 0 | -15,285,553 | -26,838,903 | 42,577,041 | 32,248,109 | 10,328,932 | -12,484,376 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
BriaCell Shares Turn Volatile After Melanoma Vaccine Development Milestone
2026-08-24 12:47 · Yahoo
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
2026-08-24 11:30 · Yahoo
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
2026-08-05 11:30 · Yahoo
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)?
2026-07-18 03:15 · Yahoo
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
2026-07-16 11:30 · Yahoo
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
2026-07-15 11:30 · Yahoo
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
2026-07-07 11:30 · Yahoo
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
2026-06-25 11:30 · Yahoo
BriaCell Presents Positive Clinical Data at ASCO 2026
2026-06-01 11:30 · Yahoo
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
2026-05-26 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.